Avanza Fonder AB Makes New Investment in Avantor, Inc. (NYSE:AVTR)

Avanza Fonder AB purchased a new position in Avantor, Inc. (NYSE:AVTR) in the fourth quarter, HoldingsChannel reports. The firm purchased 64,936 shares of the company’s stock, valued at approximately $1,368,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. UMB Bank n.a. bought a new stake in Avantor during the third quarter worth approximately $49,000. Nisa Investment Advisors LLC raised its stake in shares of Avantor by 69.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock worth $53,000 after buying an additional 835 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Avantor by 89.9% in the third quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock valued at $70,000 after buying an additional 1,285 shares during the period. Livforsakringsbolaget Skandia Omsesidigt boosted its stake in Avantor by 278.0% during the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 5,031 shares of the company’s stock valued at $130,000 after buying an additional 3,700 shares in the last quarter. Finally, Quarry LP grew its holdings in Avantor by 4,489.1% during the second quarter. Quarry LP now owns 6,333 shares of the company’s stock worth $134,000 after acquiring an additional 6,195 shares during the period. 95.08% of the stock is currently owned by institutional investors.

Avantor Stock Down 1.9 %

AVTR stock opened at $22.14 on Friday. The company has a 50 day moving average of $21.45 and a two-hundred day moving average of $23.35. The company has a market cap of $15.07 billion, a price-to-earnings ratio of 48.13, a PEG ratio of 3.42 and a beta of 1.28. Avantor, Inc. has a 12-month low of $19.59 and a 12-month high of $28.00. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84.

Wall Street Analysts Forecast Growth

AVTR has been the topic of a number of research reports. Wells Fargo & Company dropped their target price on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a report on Monday, October 28th. Barclays reduced their price objective on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. Robert W. Baird dropped their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research report on Monday, October 28th. Royal Bank of Canada restated an “outperform” rating and issued a $34.00 price target on shares of Avantor in a research report on Thursday, September 26th. Finally, UBS Group reaffirmed a “neutral” rating and issued a $25.00 price objective (down previously from $29.00) on shares of Avantor in a research note on Friday. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Avantor has a consensus rating of “Moderate Buy” and an average price target of $27.38.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.